Compare Abbott Laboratories (ABT) vs Manchester United PLC (MANU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Manchester United PLC — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Manchester United PLC trades at $21.96 (market cap $3.85B). The key difference: Abbott Laboratories is far larger — about 43.4× Manchester United PLC's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MANU | |
|---|---|---|
Market Cap | $166.94B | $3.85B |
Sector | Health | Media |
52-Week High | $136.62 | $23.53 |
52-Week Low | $82.57 | $15.10 |
Enterprise Value | $193.69B | $4.77B |
Dividend Yield | 2.63% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Manchester United (MANU) trades at $22.35, down 3.29% on the day, with a bullish technical outlook from moving averages but mixed oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, while revenue trends show modest growth to $667M in 2025. Recent news highlights stadium expansion plans and Champions League qualification as positive catalysts, though profitability remains challenged with a net income margin of -4.96% in 2025.
The outlook is cautiously optimistic with analyst consensus leaning hold (60%) amid valuation concerns (P/S 4.25, P/B 16.21). Key opportunities include revenue upside from new stadium and European competition, while risks involve persistent losses, high debt, and sports performance volatility. The stock's proximity to its 52-week high of $24.22 suggests limited near-term upside without fundamental improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
